Literature DB >> 21314623

The implication of Pseudomonas aeruginosa biofilms in infections.

Morten T Rybtke1, Peter Ø Jensen, Niels Høiby, Michael Givskov, Tim Tolker-Nielsen, Thomas Bjarnsholt.   

Abstract

Biofilm formation by bacteria is recognized as a major problem in chronic infections due to their recalcitrance against the immune defense and available antibiotic treatment schemes. The opportunistic pathogen Pseudomonas aeruginosa has drawn special attention in this regard due to its severity of infection in the lungs of cystic fibrosis patients and in chronic wounds. In this review we address the molecular basis of biofilm development by P. aeruginosa as well as the mechanisms employed by this bacterium in the increased tolerance displayed against antimicrobials. The complex build-up of the extracellular matrix encasing the biofilm-associated bacteria as well as the elaborate signaling mechanisms employed by the bacterium enables it to withstand the continuous stresses imposed by the immune defense and administered antibiotics resulting in a state of chronic inflammation that damages the host. The immune response leading to this chronic inflammation is described. Finally, novel treatment strategies against P. aeruginosa are described including, quorum-sensing inhibition and induced biofilm-dispersion. The tolerance towards currently available antimicrobials calls for development of alternative treatment strategies where the underlying targets are less prone for resistance development as bacteria, in retrospect, have a unique ability to evade the actions of classic antibiotics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21314623     DOI: 10.2174/187152811794776222

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  22 in total

Review 1.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

2.  LuxS mediates iron-dependent biofilm formation, competence, and fratricide in Streptococcus pneumoniae.

Authors:  Claudia Trappetti; Adam J Potter; Adrienne W Paton; Marco R Oggioni; James C Paton
Journal:  Infect Immun       Date:  2011-08-29       Impact factor: 3.441

Review 3.  Multispecies biofilms and host responses: "discriminating the trees from the forest".

Authors:  R Peyyala; J L Ebersole
Journal:  Cytokine       Date:  2012-11-06       Impact factor: 3.861

4.  Taxonomy and antifungal susceptibility of clinically important Rasamsonia species.

Authors:  J Houbraken; S Giraud; M Meijer; S Bertout; J C Frisvad; J F Meis; J P Bouchara; R A Samson
Journal:  J Clin Microbiol       Date:  2012-10-17       Impact factor: 5.948

5.  Recycling of peptidyl-tRNAs by peptidyl-tRNA hydrolase counteracts azithromycin-mediated effects on Pseudomonas aeruginosa.

Authors:  Julia Gödeke; Christian Pustelny; Susanne Häussler
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

6.  Clearance of Pseudomonas aeruginosa foreign-body biofilm infections through reduction of the cyclic Di-GMP level in the bacteria.

Authors:  Louise D Christensen; Maria van Gennip; Morten T Rybtke; Hong Wu; Wen-Chi Chiang; Morten Alhede; Niels Høiby; Thomas E Nielsen; Michael Givskov; Tim Tolker-Nielsen
Journal:  Infect Immun       Date:  2013-05-20       Impact factor: 3.441

7.  Controlling chronic Pseudomonas aeruginosa infections by strategically interfering with the sensory function of SagS.

Authors:  Jozef Dingemans; Rebecca E Al-Feghali; Gee W Lau; Karin Sauer
Journal:  Mol Microbiol       Date:  2019-03-26       Impact factor: 3.501

8.  Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.

Authors:  Sebastian Kirchner; Joanne L Fothergill; Elli A Wright; Chloe E James; Eilidh Mowat; Craig Winstanley
Journal:  J Vis Exp       Date:  2012-06-05       Impact factor: 1.355

9.  The airway microbiota in cystic fibrosis: a complex fungal and bacterial community--implications for therapeutic management.

Authors:  Laurence Delhaes; Sébastien Monchy; Emilie Fréalle; Christine Hubans; Julia Salleron; Sylvie Leroy; Anne Prevotat; Frédérick Wallet; Benoit Wallaert; Eduardo Dei-Cas; Telesphore Sime-Ngando; Magali Chabé; Eric Viscogliosi
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

10.  Strain-specific parallel evolution drives short-term diversification during Pseudomonas aeruginosa biofilm formation.

Authors:  Kerensa E McElroy; Janice G K Hui; Jerry K K Woo; Alison W S Luk; Jeremy S Webb; Staffan Kjelleberg; Scott A Rice; Torsten Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.